CLDX vs IDXX
Celldex Therapeutics, Inc. and Idexx Laboratories Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | CLDX | IDXX |
|---|---|---|
| Revenue | $1.5M | $4.3B |
| Net income | $-258.8M | $1.1B |
| Gross margin | 87.1% | 61.8% |
| Net margin | · | 24.6% |
| Return on equity | −40.6% | 66.2% |
| Diluted EPS | −$3.90 | $13.08 |
| Dividend / share | · | · |
| Payout ratio | · | · |
| Free cash flow | $-213.7M | $1.1B |
| Equity | $527.2M | $1.6B |
| Net debt / equity | · | 0.17× |
| Current ratio | 10.49× | 1.23× |
| Revenue CAGR 5y | −26.9% | 9.7% |
| Profit CAGR 5y | · | 12.7% |
IDXX bills 2785.6× the revenue of CLDX, and CLDX closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | CLDX | IDXX |
|---|---|---|
| FY2025 | $1.5M | $4.3B |
| FY2024 | $7.0M | $3.9B |
| FY2023 | $6.9M | $3.7B |
| FY2022 | $2.4M | $3.4B |
| FY2021 | $4.7M | $3.2B |
| FY2020 | $7.4M | $2.7B |
| FY2019 | $3.6M | $2.4B |
| FY2018 | $9.5M | $2.2B |
| FY2017 | $12.7M | $2.0B |
| FY2016 | $6.8M | $1.8B |
Bottom line
| Fiscal year | CLDX | IDXX |
|---|---|---|
| FY2025 | $-258.8M | $1.1B |
| FY2024 | $-157.9M | $887.9M |
| FY2023 | $-141.4M | $845.0M |
| FY2022 | $-112.3M | $679.1M |
| FY2021 | $-70.5M | $744.8M |
| FY2020 | $-59.8M | $581.8M |
| FY2019 | $-50.9M | $427.7M |
| FY2018 | $-151.2M | $377.0M |
| FY2017 | $-93.0M | $263.1M |
| FY2016 | $-128.5M | $222.0M |
17 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −$4,302,157,000 | IDXX |
| FY2024 | −$3,890,484,000 | IDXX |
| FY2023 | −$3,654,070,000 | IDXX |
| FY2022 | −$3,364,967,000 | IDXX |
| FY2021 | −$3,210,709,000 | IDXX |
| FY2020 | −$2,699,237,000 | IDXX |
| FY2019 | −$2,403,335,000 | IDXX |
| FY2018 | −$2,203,704,000 | IDXX |
| FY2017 | −$1,956,315,000 | IDXX |
| FY2016 | −$1,768,637,000 | IDXX |
| FY2015 | −$1,596,412,000 | IDXX |
| FY2014 | −$1,482,221,000 | IDXX |
| FY2013 | −$1,372,947,000 | IDXX |
| FY2012 | −$1,282,136,000 | IDXX |
| FY2011 | −$1,209,424,000 | IDXX |
| FY2010 | −$1,056,599,000 | IDXX |
| FY2009 | −$1,016,453,000 | IDXX |
IDXX has reported the higher revenue in every one of these 17 fiscal years. The gap has widened since the earliest year compared.
17 of 18 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
IDXX's return on equity has been more volatile than CLDX's over the 12 comparable fiscal years — 37.6 percentage points of standard deviation against 17.2.
12 of 18 comparable fiscal years — a year missing data on either side is not counted.
Year by year
IDXX led in return on equity in every one of the 12 comparable fiscal years — a structural lead, not a recent swing.
12 of 18 comparable fiscal years — a year missing data on either side is not counted.